All In Biotech

Drug Trial Radar · NCT04037072

Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures

GI-108: Randomized Controlled Double-Blinded Trial Assessing the Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures

Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 3, 2020

Primary completion

Mar 15, 2022

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Fox Chase Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates Mitomycin C as treatment for dysphagia in adult subjects with documented complex esophageal anastomotic strictures. Patients will be randomized in a double-blinded fashion to topical application of normal saline (NS) or Mitomycin C (MMC) at the time of time of index procedure.

Conditions

  • Esophageal Stenosis
  • Anastomotic Stenosis

Interventions

  • Mitomycin CDrug

    Topical application of Mytomycin C (MMC)

  • ControlOther

    Topical application of Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dysphagia ≥ grade 1 after the dilation procedureTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.